Weight-loss drug also targets metabolic risk factors.

Australian Doctor,  November, 2005  

• E-mail
• Print
• Link

by Jane McCredie

NEJM A drug that helps people lose weight by blocking pleasure centres in the brain also significantly improves metabolic risk factors in overweight people at increased risk of cardiovascular disease, a study shows.

The selective cannabinoid-1 receptor blocker, rimonabant, significantly reduced body weight, waist circumference and various other risk factors in overweight patients with dyslipidaemia, according to a randomised controlled trial reported in the New England Journal of Medicine (17 November).

Patients taking rimonabant 20mg a day lost an average ...

Read the rest of this article with a Free Trial at HighBeam Research.